Tweet
VolitionRX (NYSEAMERICAN:VNRX) posted its quarterly earnings data on Wednesday. The medical research company reported ($0.14) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.14), Fidelity Earnings reports.
Shares of VNRX traded down $0.05 during midday trading on Thursday, reaching $2.70. The stock had a trading volume of 53,986 shares, compared to its average volume of 109,215. VolitionRX has a 52 week low of $1.44 and a 52 week high of $4.00. Get VolitionRX alerts:
In related news, Director Guy Archibald Innes bought 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 16th. The shares were acquired at an average cost of $2.00 per share, for a total transaction of $100,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink .
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore. Receive News & Ratings for VolitionRX analysts' ratings for VolitionRX and related companies daily email
